| Recruiting | Aberrant Expression of CD56 in Patients With Hematologic Malignancies. NCT04546945 | Asmaa Hassan mohamed Abdel Mawjoud | — |
| Recruiting | Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention NCT06926595 | Milton S. Hershey Medical Center | Phase 2 |
| Suspended | Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High NCT07285668 | University of Wisconsin, Madison | N/A |
| Not Yet Recruiting | The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytar NCT07441967 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Wi NCT07359859 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therap NCT07186192 | City of Hope Medical Center | Phase 3 |
| Recruiting | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916 | Incyte Corporation | Phase 1 |
| Not Yet Recruiting | A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies NCT07316907 | YANRU WANG | Phase 1 |
| Not Yet Recruiting | A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancie NCT07255898 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide- NCT07162038 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With NCT07117175 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Recruiting | PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Sync NCT06665100 | Pulmotect, Inc. | Phase 2 |
| Completed | Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients NCT07200583 | Ting YANG | — |
| Recruiting | This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile NCT06756451 | Nanjing RegeneCore Biotech Co., Ltd. | Phase 1 |
| Recruiting | Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who NCT06807606 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer NCT06823167 | Immunome, Inc. | Phase 1 |
| Completed | Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single NCT06900114 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Enrolling By Invitation | Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product NCT06925685 | Allogene Therapeutics | — |
| Active Not Recruiting | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants Wit NCT06645886 | Kumquat Biosciences Inc. | Phase 1 |
| Completed | Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound NCT06455553 | Centre Hospitalier Annecy Genevois | N/A |
| Recruiting | DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics NCT06296368 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | IVIG for Infection Prevention After CAR-T-Cell Therapy NCT05952804 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Ly NCT06378138 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant NCT05849207 | Ronald Paquette | Phase 1 |
| Recruiting | Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation NCT06028828 | University of California, Irvine | Phase 2 |
| Completed | RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies NCT05923541 | Henan Cancer Hospital | EARLY_Phase 1 |
| Completed | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies NCT05371054 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax NCT05724121 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Recruiting | Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplant NCT05470491 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hem NCT07036133 | Acrotech Biopharma Inc. | Phase 1 |
| Completed | An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies NCT05433090 | University of Rochester | N/A |
| Recruiting | Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled NCT06465433 | Incyte Corporation | Phase 2 |
| Active Not Recruiting | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy NCT05104775 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | The Effect of Lavender Oil on Fatigue and Sleep Quality NCT05808296 | Istanbul Aydın University | N/A |
| Unknown | A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancie NCT05028478 | Curon Biopharmaceutical (Australia) Co Pty Ltd | Phase 1 / Phase 2 |
| Recruiting | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malign NCT04588922 | Sellas Life Sciences Group | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) NCT04728893 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma NCT04696809 | Janssen Pharmaceutical K.K. | Phase 1 / Phase 2 |
| Unknown | Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology NCT04758442 | Ciusss de L'Est de l'Île de Montréal | N/A |
| Unknown | An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Progra NCT04581187 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies NCT04538599 | He Huang | Phase 1 |
| Withdrawn | Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation NCT04428918 | National Cancer Institute (NCI) | — |
| Completed | Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease NCT04112810 | Medical College of Wisconsin | Phase 2 |
| Unknown | Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients NCT04478916 | Lorenza Scotti | — |
| Terminated | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors NCT04214093 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation NCT04098393 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With NCT03557619 | AbbVie | Phase 1 |
| Recruiting | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treat NCT03486873 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies NCT03537482 | Ascentage Pharma Group Inc. | EARLY_Phase 1 |
| Terminated | GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of NCT03320642 | Incyte Corporation | Phase 1 |
| Recruiting | Register of Blood Stem Cell Transplantation NCT04263857 | Technical University of Munich | — |
| Withdrawn | Consolidation Therapy in Patients With Hematologic Malignancies NCT02709993 | Kiromic BioPharma Inc. | Phase 1 / Phase 2 |
| Withdrawn | Therapy for Progressive and/or Refractory Hematologic Malignancies NCT02223312 | Kiromic BioPharma Inc. | Phase 1 / Phase 2 |
| Completed | Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients NCT03609840 | University of California, San Francisco | — |
| Terminated | Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia NCT02964325 | Terumo BCTbio | N/A |
| Terminated | Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies NCT02985554 | University of Chicago | Phase 1 |
| Completed | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and He NCT03082209 | AbbVie | Phase 1 |
| Completed | Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT NCT02988466 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies NCT02743351 | Fate Therapeutics | Phase 1 / Phase 2 |
| Unknown | Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation NCT02921685 | Institut Paoli-Calmettes | Phase 1 |
| Completed | Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generati NCT02844400 | UNC Lineberger Comprehensive Cancer Center | — |
| Completed | Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transpl NCT02301065 | St. Jude Children's Research Hospital | — |
| Completed | Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients NCT03212560 | Gazi University | — |
| Withdrawn | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies NCT02487459 | Bellicum Pharmaceuticals | Phase 1 |
| Withdrawn | Treg Cells for AGVHD in Non-myeloablative UCB Transplant NCT02118311 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generati NCT02786628 | UNC Lineberger Comprehensive Cancer Center | — |
| Terminated | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors NCT02663518 | Pfizer | Phase 1 |
| Completed | Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT) NCT03609814 | University of California, San Francisco | — |
| Unknown | Matching Patients With Hematologic Malignancy to Adequate Clinical Trials NCT02758080 | Seoul National University Hospital | N/A |
| Unknown | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies NCT02503033 | Hutchison Medipharma Limited | Phase 1 |
| Completed | A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders NCT02494258 | Celgene | Phase 2 |
| Active Not Recruiting | Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Deple NCT02600208 | Julie-An M. Talano | Phase 2 / Phase 3 |
| Enrolling By Invitation | Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies NCT02473757 | National Cancer Institute (NCI) | — |
| Completed | Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients NCT03609827 | University of California, San Francisco | — |
| Completed | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH NCT02492737 | Agios Pharmaceuticals, Inc. | Phase 1 |
| Completed | Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host D NCT02342613 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Withdrawn | Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies NCT02343679 | Anne Beaven, MD | Phase 2 |
| Recruiting | Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study NCT02457962 | Mayo Clinic | — |
| Completed | Safety of Romiplostim (Nplate®) Following UCBT NCT02046291 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Unknown | A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignanc NCT02386332 | Instituto de Investigacion Sanitaria La Fe | — |
| Enrolling By Invitation | Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology NCT02315599 | National Cancer Institute (NCI) | — |
| Terminated | A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies NCT02354417 | Fate Therapeutics | Phase 1 |
| Completed | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Tr NCT02129582 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies NCT02145403 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Unknown | Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation NCT01788605 | The Catholic University of Korea | Phase 2 |
| Terminated | BGJ398 for Patients With Tumors With FGFR Genetic Alterations NCT02160041 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | LGX818 for Patients With BRAFV600 Mutated Tumors NCT01981187 | Pfizer | Phase 2 |
| Withdrawn | Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord NCT01882374 | Tarix Pharmaceuticals | Phase 2 |
| Withdrawn | Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood NCT01882387 | Tarix Pharmaceuticals | Phase 2 |
| Completed | Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy NCT02139280 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Completed | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Imp NCT01949545 | Amgen | Phase 1 |
| Unknown | Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Ho NCT02032446 | A.O. Ospedale Papa Giovanni XXIII | Phase 1 / Phase 2 |
| Completed | Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction NCT01912222 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate NCT01844869 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 |
| Recruiting | Clinical Cohort of Lymphoma Patients in Malawi NCT02835911 | UNC Lineberger Comprehensive Cancer Center | — |
| Active Not Recruiting | Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation NCT01810588 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life NCT01930981 | Fred Hutchinson Cancer Center | — |
| Terminated | A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies NCT02623439 | University of California, San Diego | Phase 2 |
| Terminated | Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation NCT01749293 | University of Illinois at Chicago | Phase 2 |
| Terminated | The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant NCT01627314 | Fate Therapeutics | Phase 2 |
| Completed | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma NCT01345019 | Amgen | Phase 3 |
| Completed | Phase I Study of mPEG-R-Crisantaspase Given IV NCT01551524 | Jazz Pharmaceuticals | Phase 1 |
| Completed | A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care NCT01725022 | Duke University | N/A |
| Terminated | Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies NCT01622556 | University of Virginia | Phase 2 |
| Completed | Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation NCT01460420 | European Myeloma Network B.V. | Phase 1 / Phase 2 |
| Completed | Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia NCT01380756 | Amgen | Phase 1 |
| Recruiting | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545 | Center for International Blood and Marrow Transplant Research | — |
| Terminated | A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies NCT01476657 | SecuraBio | Phase 1 |
| Completed | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tol NCT01375842 | Genentech, Inc. | Phase 1 |
| Completed | Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparati NCT01328496 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies NCT01260545 | Janssen Research & Development, LLC | Phase 1 |
| Completed | AMG 319 Lymphoid Malignancy FIH NCT01300026 | Amgen | Phase 1 |
| Terminated | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps NCT01350258 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT01237639 | Ottawa Hospital Research Institute | Phase 3 |
| Completed | Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Ad NCT01351350 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation NCT01316549 | University of California, San Francisco | — |
| Completed | Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. NCT00890500 | Fate Therapeutics | Phase 1 |
| Completed | Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies NCT01203722 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Recruiting | Elderly CAncer Patient NCT02884375 | Assistance Publique - Hôpitaux de Paris | — |
| Terminated | Dose Escalation of IPI-493 in Hematologic Malignancies NCT01193491 | Infinity Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation NCT01217723 | McMaster University | Phase 3 |
| Completed | A Study Of PF-04449913 In Select Hematologic Malignancies NCT00953758 | Pfizer | Phase 1 |
| Completed | Umbilical Cord Transplantation for the Elderly Population NCT01484470 | Loyola University | Phase 2 |
| Completed | Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide NCT01010217 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Anidulafungin in Patients With Hematologic Malignancies NCT01053884 | Elisabethinen Hospital | Phase 2 |
| Completed | Cytokine Induced Killer (CIK) Cells In Leukemia Patients NCT01186809 | A.O. Ospedale Papa Giovanni XXIII | Phase 2 |
| Completed | Repeat Dose Safety Study for Compound to Treat Hematologic Cancer NCT00881946 | Accenture | Phase 1 / Phase 2 |
| Completed | Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets NCT01687231 | Duke University | N/A |
| Completed | Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regim NCT00824135 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplan NCT00810602 | Pavan Reddy, MD | Phase 1 / Phase 2 |
| Completed | Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia NCT00677859 | Healios K.K. | Phase 1 |
| Completed | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple My NCT00722488 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies NCT00660920 | Ariad Pharmaceuticals | Phase 1 |
| Completed | Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) NCT00750737 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malig NCT00675831 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation NCT01081405 | Fondazione EMN Italy Onlus | N/A |
| Completed | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Mye NCT00469729 | Gamida Cell -Teva Joint Venture Ltd. | Phase 2 / Phase 3 |
| Completed | Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies NCT00521859 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Adult Double Cord Blood Transplant Study NCT00514579 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | Phase II Trial of Pentostatin and Targeted Busulfan NCT00496340 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned Wi NCT00843947 | University of California, Davis | Phase 2 |
| Unknown | A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells NCT00596999 | Celgene Corporation | — |
| Completed | A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malign NCT00477542 | Indiana University School of Medicine | Phase 1 |
| Completed | A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine NCT00741234 | S*BIO | Phase 1 |
| Terminated | Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies NCT00689884 | Dartmouth-Hitchcock Medical Center | N/A |
| Withdrawn | In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells NCT00731705 | Indiana University School of Medicine | — |
| Completed | Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies NCT00642031 | Prescient Therapeutics, Ltd. | Phase 1 |
| Completed | Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allog NCT00369226 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduce NCT00402714 | Yale University | Phase 2 |
| Completed | Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation NCT00355407 | Dana-Farber Cancer Institute | N/A |
| Completed | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies NCT00405743 | Clavis Pharma | Phase 1 / Phase 2 |
| Completed | A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative NCT00429143 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic NCT00189488 | Swedish Orphan Biovitrum | Phase 2 |
| Completed | Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patien NCT00993486 | Kiadis Pharma | Phase 1 / Phase 2 |
| Completed | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) NCT00086125 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies NCT00741455 | Dartmouth-Hitchcock Medical Center | N/A |
| Terminated | G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion NCT00228813 | Emory University | N/A |
| Completed | Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Ve NCT00429416 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies NCT00202917 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Completed | Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies NCT00079391 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies NCT00113048 | Genzyme, a Sanofi Company | Phase 1 |
| Completed | Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells NCT00770523 | Cooperative Study Group A for Hematology | — |
| Completed | Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoiet NCT00138112 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Completed | Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support NCT00506857 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) NCT00231309 | Emory University | N/A |
| Completed | Infusional C-myb ASODN in Advanced Hematologic Malignancies NCT00780052 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transpla NCT00146614 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation NCT00144703 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBS NCT00693927 | University of Liege | Phase 2 |
| Completed | Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies NCT00061620 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Stem Cell Transplant for Hematologic Diseases NCT00058825 | Baylor College of Medicine | Phase 1 / Phase 2 |
| Completed | Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancie NCT00208923 | Emory University | Phase 2 |
| Completed | IUdR/BUdR Cell Cycle Labelling NCT00042250 | M.D. Anderson Cancer Center | N/A |
| Temporarily Not Available | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies NCT07346105 | Orca Biosystems, Inc. | — |
| Available | Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrel NCT01881334 | Joanne Kurtzberg, MD | — |